OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, October 30th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.

OncoMed Pharmaceuticals (NASDAQ:OMED) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.10. The firm had revenue of $6.20 million for the quarter, compared to analysts’ expectations of $6.08 million. OncoMed Pharmaceuticals’s revenue for the quarter was down 7.0% on a year-over-year basis. During the same period last year, the firm posted ($0.91) earnings per share. On average, analysts expect OncoMed Pharmaceuticals to post $-1.85 EPS for the current fiscal year and $-1.67 EPS for the next fiscal year.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) traded down 0.27% during midday trading on Monday, hitting $3.75. 29,408 shares of the stock traded hands. OncoMed Pharmaceuticals, Inc. has a one year low of $2.91 and a one year high of $10.89. The company’s 50-day moving average is $4.40 and its 200-day moving average is $4.07. The company’s market cap is $141.11 million.

ILLEGAL ACTIVITY WARNING: “OncoMed Pharmaceuticals, Inc. (OMED) Set to Announce Quarterly Earnings on Monday” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/10/23/oncomed-pharmaceuticals-inc-omed-set-to-announce-quarterly-earnings-on-monday.html.

Several research analysts have recently weighed in on OMED shares. Jefferies Group LLC restated a “buy” rating and issued a $5.00 target price on shares of OncoMed Pharmaceuticals in a research note on Sunday, July 9th. Zacks Investment Research upgraded shares of OncoMed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research note on Wednesday, October 4th. Piper Jaffray Companies set a $5.00 price objective on shares of OncoMed Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, July 10th. SunTrust Banks, Inc. reiterated a “hold” rating and set a $4.00 price objective on shares of OncoMed Pharmaceuticals in a research note on Friday, October 6th. Finally, Cantor Fitzgerald reiterated a “hold” rating and set a $6.00 price objective on shares of OncoMed Pharmaceuticals in a research note on Tuesday, September 19th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $5.84.

OncoMed Pharmaceuticals Company Profile

OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).

Earnings History for OncoMed Pharmaceuticals (NASDAQ:OMED)

Receive News & Ratings for OncoMed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoMed Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.